What is 10X Genomics, Inc.'s earnings per share (EPS)?

10X Genomics, Inc. (TXG) reported diluted earnings per share of $-0.35 for fiscal year 2025. This represents a 77.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

10X Genomics, Inc. Financials

TXG

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows 10X Genomics, Inc. (TXG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 51/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

10X Genomics, Inc. has an operating margin of -9.5%, meaning the company retains $-9 of operating profit per $100 of revenue. This below-average margin results in a low score of 1/100, suggesting thin profitability after operating expenses. This is up from -31.9% the prior year.

Growth

10X Genomics, Inc.'s revenue grew 5.2% year-over-year to $642.8M, a solid pace of expansion. This earns a growth score of 42/100.

Leverage

10X Genomics, Inc. carries a low D/E ratio of 0.31, meaning only $0.31 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.46, 10X Genomics, Inc. holds $4.46 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.

Cash Flow

10X Genomics, Inc. converts 20.2% of revenue into free cash flow ($130.1M). This strong cash generation earns a score of 76/100.

Returns

10X Genomics, Inc. generates a -5.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -25.7% the prior year.

Piotroski F-Score Neutral

4/9

10X Genomics, Inc. passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-3.12x

For every $1 of reported earnings, 10X Genomics, Inc. generates $-3.12 in operating cash flow ($136.1M OCF vs -$43.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$642.8M

YoY+5.2%

5Y CAGR+16.6%

10X Genomics, Inc. generated $642.8M in revenue in fiscal year 2025. This represents an increase of 5.2% from the prior year.

EBITDA

-$24.8M

YoY+84.4%

10X Genomics, Inc.'s EBITDA was -$24.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 84.4% from the prior year.

Net Income

-$43.5M

YoY+76.2%

10X Genomics, Inc. reported -$43.5M in net income in fiscal year 2025. This represents an increase of 76.2% from the prior year.

EPS (Diluted)

$-0.35

YoY+77.0%

10X Genomics, Inc. earned $-0.35 per diluted share (EPS) in fiscal year 2025. This represents an increase of 77.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$130.1M

YoY+2371.2%

10X Genomics, Inc. generated $130.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2371.2% from the prior year.

Cash & Debt

$474.0M

YoY+37.8%

5Y CAGR-6.5%

10X Genomics, Inc. held $474.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

128M

YoY+4.4%

5Y CAGR+3.3%

10X Genomics, Inc. had 128M shares outstanding in fiscal year 2025. This represents an increase of 4.4% from the prior year.

Margins & Returns

Gross Margin

69.0%

YoY+1.2pp

5Y CAGR-11.4pp

10X Genomics, Inc.'s gross margin was 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.

Operating Margin

-9.5%

YoY+22.4pp

5Y CAGR+169.3pp

10X Genomics, Inc.'s operating margin was -9.5% in fiscal year 2025, reflecting core business profitability. This is up 22.4 percentage points from the prior year.

Net Margin

-6.8%

YoY+23.1pp

5Y CAGR+174.8pp

10X Genomics, Inc.'s net profit margin was -6.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 23.1 percentage points from the prior year.

Return on Equity

-5.5%

YoY+20.3pp

5Y CAGR+68.0pp

10X Genomics, Inc.'s ROE was -5.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$238.6M

YoY-9.8%

5Y CAGR+14.1%

10X Genomics, Inc. invested $238.6M in research and development in fiscal year 2025. This represents a decrease of 9.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5.9M

YoY-52.1%

5Y CAGR-30.5%

10X Genomics, Inc. invested $5.9M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 52.1% from the prior year.

TXG Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$642.8M+5.2%	$610.8M-1.3%	$618.7M+19.8%	$516.4M+5.3%	$490.5M+64.1%	$298.8M
Cost of Revenue	$198.9M+1.3%	$196.3M-6.3%	$209.4M+74.0%	$120.4M+62.5%	$74.1M+26.7%	$58.5M
Gross Profit	$443.9M+7.1%	$414.5M+1.3%	$409.3M+3.4%	$396.0M-4.9%	$416.4M+73.2%	$240.4M
R&D Expenses	$238.6M-9.8%	$264.7M-2.1%	$270.3M+1.8%	$265.7M+25.5%	$211.8M+71.6%	$123.4M
SG&A Expenses	$316.1M-8.2%	$344.3M+0.3%	$343.3M+15.1%	$298.3M+15.8%	$257.6M+27.3%	$202.3M
Operating Income	-$61.0M+68.7%	-$194.6M+26.7%	-$265.3M-58.0%	-$167.9M-221.4%	-$52.3M+90.2%	-$534.1M
Interest Expense	$0-100.0%	$4K-87.9%	$33K-93.1%	$476K-45.0%	$866K-48.5%	$1.7M
Income Tax	$3.6M-26.2%	$4.9M-22.2%	$6.3M+57.3%	$4.0M-10.6%	$4.5M-45.4%	$8.3M
Net Income	-$43.5M+76.2%	-$182.6M+28.4%	-$255.1M-53.7%	-$166.0M-185.1%	-$58.2M+89.3%	-$542.7M
EPS (Diluted)	$-0.35+77.0%	$-1.52+30.3%	$-2.18-49.3%	$-1.46-175.5%	$-0.53+90.1%	$-5.37

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$166.0M+11.4%	$149.0M-13.8%	$172.9M+11.6%	$154.9M-6.1%	$165.0M+8.8%	$151.7M-0.9%	$153.1M+8.6%	$141.0M
Cost of Revenue	$53.0M+8.8%	$48.7M+1.8%	$47.8M-3.3%	$49.4M-8.6%	$54.1M+19.5%	$45.3M-7.4%	$48.9M+1.6%	$48.1M
Gross Profit	$113.0M+12.7%	$100.3M-19.8%	$125.1M+18.6%	$105.4M-5.0%	$111.0M+4.3%	$106.4M+2.1%	$104.2M+12.2%	$92.9M
R&D Expenses	$56.0M-2.1%	$57.2M-6.6%	$61.2M-4.7%	$64.2M-4.1%	$67.0M+1.2%	$66.2M+5.2%	$62.9M-8.3%	$68.6M
SG&A Expenses	$76.6M+1.7%	$75.4M+1.2%	$74.4M-17.0%	$89.7M-4.4%	$93.8M+14.8%	$81.7M-1.6%	$83.0M-3.2%	$85.8M
Operating Income	-$19.5M+39.4%	-$32.2M-207.0%	$30.1M+176.6%	-$39.3M+21.1%	-$49.8M-20.1%	-$41.5M+0.6%	-$41.7M+32.1%	-$61.5M
Interest Expense	$0+100.0%	-$3K-200.0%	$3K	$0	$0-100.0%	$2K+100.0%	$1K0.0%	$1K
Income Tax	$1.1M+244.5%	-$733K-129.8%	$2.5M+188.6%	$852K+31.5%	$648K-50.7%	$1.3M+60.8%	$818K-61.9%	$2.1M
Net Income	-$16.3M+40.8%	-$27.5M-179.5%	$34.5M+200.5%	-$34.4M+29.9%	-$49.0M-37.1%	-$35.8M+5.7%	-$37.9M+36.8%	-$59.9M
EPS (Diluted)	N/A	$-0.22-178.6%	$0.28+200.0%	$-0.28	N/A	$-0.30+6.3%	$-0.32+36.0%	$-0.50

TXG Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$1.0B+13.4%	$918.6M-4.8%	$965.1M-6.2%	$1.0B+1.0%	$1.0B+9.6%	$929.3M
Current Assets	$684.5M+17.1%	$584.4M-2.0%	$596.0M-6.1%	$635.0M-15.1%	$747.6M-3.5%	$774.4M
Cash & Equivalents	$474.0M+37.8%	$344.1M-4.2%	$359.3M+63.5%	$219.7M-62.6%	$587.4M-11.5%	$663.6M
Inventory	$56.3M-32.2%	$83.1M+12.8%	$73.7M-9.7%	$81.6M+36.1%	$60.0M+100.2%	$30.0M
Accounts Receivable	$47.0M-46.5%	$87.9M-23.5%	$114.8M+10.2%	$104.2M+22.2%	$85.3M+66.5%	$51.2M
Goodwill	$4.5M0.0%	$4.5M0.0%	$4.5M0.0%	$4.5M0.0%	$4.5M	$0
Total Liabilities	$245.0M+17.5%	$208.5M-7.0%	$224.1M+0.4%	$223.2M+10.9%	$201.3M+5.8%	$190.3M
Current Liabilities	$153.5M+30.5%	$117.6M-7.5%	$127.2M-2.9%	$131.0M+18.7%	$110.4M-6.6%	$118.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$0
Total Equity	$796.3M+12.1%	$710.1M-4.2%	$741.0M-8.0%	$805.7M-1.4%	$817.6M+10.6%	$739.1M
Retained Earnings	-$1.5B-3.0%	-$1.5B-14.2%	-$1.3B-24.8%	-$1.0B-19.2%	-$863.3M-7.2%	-$805.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$1.0B+1.4%	$1.0B+4.8%	$980.0M+8.5%	$903.4M-1.7%	$918.6M-2.0%	$937.8M+0.9%	$929.7M+0.7%	$922.9M
Current Assets	$684.5M+3.7%	$659.8M+0.6%	$655.7M+13.1%	$579.7M-0.8%	$584.4M-1.6%	$593.9M+2.5%	$579.2M+2.1%	$567.1M
Cash & Equivalents	$474.0M+9.5%	$432.7M+8.8%	$397.7M+5.5%	$377.1M+9.6%	$344.1M-13.6%	$398.2M+4.8%	$379.8M+6.8%	$355.8M
Inventory	$56.3M-9.1%	$62.0M-10.2%	$69.0M-7.7%	$74.7M-10.1%	$83.1M-11.6%	$94.0M+6.5%	$88.3M+6.1%	$83.2M
Accounts Receivable	$47.0M+7.4%	$43.8M-12.4%	$50.0M-4.9%	$52.5M-40.2%	$87.9M+5.2%	$83.5M-8.4%	$91.2M-0.1%	$91.3M
Goodwill	$4.5M0.0%	$4.5M0.0%	$4.5M0.0%	$4.5M0.0%	$4.5M0.0%	$4.5M0.0%	$4.5M0.0%	$4.5M
Total Liabilities	$245.0M+1.2%	$242.2M+17.2%	$206.7M+5.2%	$196.5M-5.8%	$208.5M-3.0%	$215.0M+4.6%	$205.6M+0.8%	$204.1M
Current Liabilities	$153.5M+4.2%	$147.3M+31.3%	$112.2M+4.0%	$107.9M-8.3%	$117.6M-3.0%	$121.2M+9.2%	$111.0M+2.1%	$108.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$796.3M+1.4%	$785.1M+1.5%	$773.3M+9.4%	$706.9M-0.5%	$710.1M-1.8%	$722.8M-0.2%	$724.1M+0.7%	$718.8M
Retained Earnings	-$1.5B-1.1%	-$1.5B-1.9%	-$1.5B+2.3%	-$1.5B-2.3%	-$1.5B-3.5%	-$1.4B-2.6%	-$1.4B-2.8%	-$1.3B

TXG Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$136.1M+1941.6%	$6.7M+143.9%	-$15.2M+54.8%	-$33.6M-57.2%	-$21.4M+90.2%	-$217.9M
Capital Expenditures	$5.9M-52.1%	$12.4M-74.5%	$48.6M-63.1%	$131.7M+30.0%	$101.3M+176.2%	$36.7M
Free Cash Flow	$130.1M+2371.2%	-$5.7M+91.0%	-$63.8M+61.4%	-$165.3M-34.7%	-$122.7M+51.8%	-$254.6M
Investing Cash Flow	-$13.4M+58.8%	-$32.6M-124.4%	$133.5M+138.0%	-$350.9M-228.8%	-$106.7M-178.0%	-$38.4M
Financing Cash Flow	$6.8M-37.7%	$10.9M-20.2%	$13.7M-13.6%	$15.8M-55.2%	$35.3M-92.5%	$468.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$40.8M-5.6%	$43.2M+144.0%	$17.7M-48.4%	$34.4M+609.1%	-$6.7M-131.2%	$21.6M+188.7%	$7.5M+147.7%	-$15.7M
Capital Expenditures	$1.8M+158.7%	$687K-56.5%	$1.6M-16.6%	$1.9M-30.3%	$2.7M-30.2%	$3.9M+35.1%	$2.9M-1.1%	$2.9M
Free Cash Flow	$39.0M-8.3%	$42.5M+163.7%	$16.1M-50.3%	$32.5M+443.0%	-$9.5M-153.3%	$17.8M+284.4%	$4.6M+124.8%	-$18.6M
Investing Cash Flow	-$1.8M+79.5%	-$8.8M-837.3%	-$939K+50.4%	-$1.9M+96.3%	-$51.6M-1326.0%	-$3.6M-130.3%	$11.9M+12.4%	$10.6M
Financing Cash Flow	$2.2M+263.4%	$617K-82.5%	$3.5M+734.6%	$422K-90.7%	$4.5M+2795.5%	$156K-96.6%	$4.6M+181.0%	$1.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TXG Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	69.0%+1.2pp	67.9%+1.7pp	66.1%-10.5pp	76.7%-8.2pp	84.9%+4.4pp	80.4%
Operating Margin	-9.5%+22.4pp	-31.9%+11.0pp	-42.9%-10.4pp	-32.5%-21.9pp	-10.7%+168.1pp	-178.7%
Net Margin	-6.8%+23.1pp	-29.9%+11.3pp	-41.2%-9.1pp	-32.1%-20.3pp	-11.9%+169.7pp	-181.6%
Return on Equity	-5.5%+20.3pp	-25.7%+8.7pp	-34.4%-13.8pp	-20.6%-13.5pp	-7.1%+66.3pp	-73.4%
Return on Assets	-4.2%+15.7pp	-19.9%+6.5pp	-26.4%-10.3pp	-16.1%-10.4pp	-5.7%+52.7pp	-58.4%
Current Ratio	4.46-0.5	4.97+0.3	4.69-0.2	4.85-1.9	6.77+0.2	6.56
Debt-to-Equity	0.31+0.0	0.290.0	0.30+0.0	0.28+0.0	0.25+0.2	0.00
FCF Margin	20.2%+21.2pp	-0.9%+9.4pp	-10.3%+21.7pp	-32.0%-7.0pp	-25.0%+60.2pp	-85.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	68.1%+0.8pp	67.3%-5.0pp	72.3%+4.3pp	68.1%+0.8pp	67.2%-2.9pp	70.2%+2.1pp	68.1%+2.2pp	65.9%
Operating Margin	-11.8%+9.9pp	-21.6%-39.1pp	17.4%+42.8pp	-25.4%+4.8pp	-30.2%-2.8pp	-27.4%-0.1pp	-27.3%+16.3pp	-43.6%
Net Margin	-9.8%+8.7pp	-18.4%-38.4pp	20.0%+42.1pp	-22.2%+7.5pp	-29.7%-6.1pp	-23.6%+1.2pp	-24.8%+17.8pp	-42.5%
Return on Equity	-2.0%+1.5pp	-3.5%-8.0pp	4.5%+9.3pp	-4.9%+2.0pp	-6.9%-2.0pp	-5.0%+0.3pp	-5.2%+3.1pp	-8.3%
Return on Assets	-1.6%+1.1pp	-2.7%-6.2pp	3.5%+7.3pp	-3.8%+1.5pp	-5.3%-1.5pp	-3.8%+0.3pp	-4.1%+2.4pp	-6.5%
Current Ratio	4.46-0.0	4.48-1.4	5.84+0.5	5.37+0.4	4.97+0.1	4.90-0.3	5.220.0	5.22
Debt-to-Equity	0.310.0	0.31+0.0	0.27-0.0	0.28-0.0	0.290.0	0.30+0.0	0.280.0	0.28
FCF Margin	23.5%-5.0pp	28.5%+19.2pp	9.3%-11.6pp	21.0%+26.7pp	-5.7%-17.4pp	11.7%+8.7pp	3.0%+16.2pp	-13.2%

Similar Companies

Certara, Inc. CERT

$860.9M

Omnicell Com OMCL

$1.6B

Phreesia PHR

$507.8M

Schrodinger, Inc. SDGR

$854.9M

Goodrx Holdings, Inc. GDRX

$702.3M

Frequently Asked Questions

What is 10X Genomics, Inc.'s annual revenue?

10X Genomics, Inc. (TXG) reported $642.8M in total revenue for fiscal year 2025. This represents a 5.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is 10X Genomics, Inc.'s revenue growing?

10X Genomics, Inc. (TXG) revenue grew by 5.2% year-over-year, from $610.8M to $642.8M in fiscal year 2025.

Is 10X Genomics, Inc. profitable?

No, 10X Genomics, Inc. (TXG) reported a net income of -$43.5M in fiscal year 2025, with a net profit margin of -6.8%.

What is 10X Genomics, Inc.'s EBITDA?

10X Genomics, Inc. (TXG) had EBITDA of -$24.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is 10X Genomics, Inc.'s gross margin?

10X Genomics, Inc. (TXG) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is 10X Genomics, Inc.'s operating margin?

10X Genomics, Inc. (TXG) had an operating margin of -9.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is 10X Genomics, Inc.'s net profit margin?

10X Genomics, Inc. (TXG) had a net profit margin of -6.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is 10X Genomics, Inc.'s return on equity (ROE)?

10X Genomics, Inc. (TXG) has a return on equity of -5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is 10X Genomics, Inc.'s free cash flow?

10X Genomics, Inc. (TXG) generated $130.1M in free cash flow during fiscal year 2025. This represents a 2371.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is 10X Genomics, Inc.'s operating cash flow?

10X Genomics, Inc. (TXG) generated $136.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are 10X Genomics, Inc.'s total assets?

10X Genomics, Inc. (TXG) had $1.0B in total assets as of fiscal year 2025, including both current and long-term assets.

What are 10X Genomics, Inc.'s capital expenditures?

10X Genomics, Inc. (TXG) invested $5.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does 10X Genomics, Inc. spend on research and development?

10X Genomics, Inc. (TXG) invested $238.6M in research and development during fiscal year 2025.

How many shares does 10X Genomics, Inc. have outstanding?

10X Genomics, Inc. (TXG) had 128M shares outstanding as of fiscal year 2025.

What is 10X Genomics, Inc.'s current ratio?

10X Genomics, Inc. (TXG) had a current ratio of 4.46 as of fiscal year 2025, which is generally considered healthy.

What is 10X Genomics, Inc.'s debt-to-equity ratio?

10X Genomics, Inc. (TXG) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is 10X Genomics, Inc.'s return on assets (ROA)?

10X Genomics, Inc. (TXG) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is 10X Genomics, Inc.'s Piotroski F-Score?

10X Genomics, Inc. (TXG) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are 10X Genomics, Inc.'s earnings high quality?

10X Genomics, Inc. (TXG) has an earnings quality ratio of -3.12x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is 10X Genomics, Inc.?

10X Genomics, Inc. (TXG) scores 51 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.